Forward Looking Statements This release contains "forward - looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward - looking statements are not based on historical fact and include statements regarding: the potential benefits of tarcocimab ; the ABC platform science continuing to advance a next set of investigational therapies for high prevalence retinal diseases; and the advancement and potential of the VETi program. Forward - looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," " cou ld," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward - looking statements are based on management's current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from tho se in or implied by such forward - looking statements. For a discussion of risks and uncertainties, and other important factors, any of which could cause our ac tua l results to differ from those contained in the forward - looking statements, see the section entitled "Risk Factors" in our most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC . These forward - looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward - looking statem ents, and readers are cautioned not to place undue reliance on such forward - looking statements. Kodiak ® , Kodiak Sciences ® , ABC ® , ABC Platform ® , ABCD TM and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions. 2